Update: Article Processing Charge (Price Changes Effective January 1, 2025)
The journal Recent Progress in Tumor will have the new APCs (New APC, 500 USD) for manuscripts submitted after 31 December 2024.
Read more about Update: Article Processing Charge (Price Changes Effective January 1, 2025)
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Liliana Belgioia from Department of Radiation Oncology, IRCCS Policlinico San Martino Hospital, Health Science Department (DISSAL), University of Genoa, Genoa, Italy, to join the Editorial Board of Recent Progress in Tumor. Prof. Dr. Liliana Belgioia has been a research assistant in radiation oncology at the University of Genoa since February 2015. In these years he participated in several clinical trials about head and neck, breast, and prostate cancer and recently he focused on the role of radiotherapy in tumor immune response. He attended several courses on scientific research methodology. Co-investigator/Principal Investigator in several national/international clinical trials. He gained expertise in managing gastrointestinal and head and neck cancer patients. From 2009 to 2011 he gained expertise in breast cancer especially in accelerated partial breast radiation therapy (IORT); from 2011 to 2013 he was involved in stereotactic body radiotherapy (thoracic malignancies). He has wide experience in palliative treatments. We appreciate Prof. Dr. Liliana Belgioia for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Michio Kurosu from University of Tennessee Health Science Center, Memphis, United States, to join the Editorial Board of Recent Progress in Tumor. Dr. Kurosu has a long-term interest in identifying new drug targets for bacterial infections and cancer chemotherapeutics. He has a broad background in organic chemistry / medicinal chemistry and protein chemistry, with special training and expertise in preclinical drug discovery (hit to lead). His research includes anticancer and antibacterial drug discoveries associated with Gram-negative bacteria, Mycobacterium spp., spore-forming bacteria (e.g., Clostridioides difficile), and solid cancers (e.g., pancreatic, breast, cervical, and ovarian cancers). As PIs on several NIH- and internally funded programs, he has studied essential enzymes for growth of Acinetobacter baumannii, Klebsiella pneumoniae, and Mycobacterium tuberculosis, and glycosyl transferases for drug discoveries of pancreatic and cervical cancers. Through these projects, he successfully collaborated with other researchers (cancer biologists, structural biochemists, microbiologists, enzymologists, geneticist, industrial medicinal chemists, pharmacologists, and a formulation scientist). One of the notable drug discovery projects is that he contributed to develop eribulin, a halichondrin B analogue, with the Harvard Professor and industrial scientists. He has developed concise syntheses of complex natural and unnatural molecules, and design/synthesized chiral small molecules, and generated small optimized libraries. He also develops convenient assays amenable to HTS. These efforts have resulted in the discovery of several new drug leads effective against dormant M. tuberculosis, C. difficile spores, and MDR-Acinetobacter baumannii. A new anticancer DPAGT1 inhibitor developed in his group is innovative. Our lab has set up cytotoxicity assays against a panel of cancer cell lines and bacterial growth inhibitory assays against batteries of pathogens including BSL3 bacteria. Basic pharmacological evaluation including in vitro ADMET studies have been routinely performed in his lab. His researches have been supported by uniquely assembled core facilities across UTHSC campus. We appreciate Prof. Dr. Michio Kurosu for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Tuan Salwani Tuan Ismail from Universiti Sains Malaysia, Minden, Malaysia, to join the Editorial Board of Recent Progress in Tumor. Chemical Pathologist with a subspecialty in Clinical Biochemistry and Endocrinology at Universiti Sains Malaysia, Health Campus Kelantan, Malaysia. She is Endocrine Laboratory Director at HUSM. She provided all the laboratory facilities and offered various specialized tests in the field of endocrine and which benefited patient management. She is welcoming others from USM and outside USM to utilize the facilities in the endocrine lab. We appreciate Prof. Dr. Tuan Salwani Tuan Ismail for her participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Ziyad S. Haidar from BioMAT'X R&D&I (HAiDAR I+D+i) LAB, Faculty of Dentistry/Faculty of Medicine, CiiB, Universidad de los Andes, Las Condes, Santiago de Chile, to join the Editorial Board of Recent Progress in Tumor. Ziyad S. Haidar is a Full Professor of Biomaterials and Tissue Engineering and the Scientific Director of the Facultad de Odontología, Universidad de los Andes in Santiago de Chile. Concurrently, Prof. Dr. Haidar is the Founder and Head of the Biomaterials, Pharmaceutical Delivery and Cranio-Maxillo-Facial Tissue Engineering Laboratory and Research Group (BioMAT'X Chile; please visit: http://www.uandes.cl/facultad-de-medicina/biomaterials-pharmaceutical.html). He serves as the Head of Innovation at the Centro de Investigación e Innovación Biomédica (CIIB) and a faculty member in the Doctoral Program (BioMedicine) at the Facultad de Medicina, Universidad de los Andes in Santiago de Chile. Also serves as Visiting Professor at several institutions, such as the Division of MaxilloFacial Surgery at the Universidad de la Frontera in Temuco. Briefly, Haidar is trained dentist, implantologist and an oral and maxillofacial surgeon with a PhD in nanobiomaterials, pharmaceuticals and tissue engineering from McGill University, Montréal, Canada; followed by a post-doctoral training residency at the Montréal Shriners Hospital (Orthopedics), McGill University Health Center, Montréal, Canada. Before moving to Chile, he served as Associate Professor of Bioceramics and the Chair of Excellence in BioEngineering at the Université de Limoges, Limoges, France and was an Assistant Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry (cross-appointment with Department of BioEngineering), University of Utah, Salt Lake City, UT, USA. Haidar served between 2010 and 2012 as Adjunct Professor of Head and Neck Surgery and the Scientific Director of the Research Center at Inha University Hospital, Seoul, South Korea. He has won several prestigious awards from the International Bone and Mineral Society, Society for Biomaterials, Canadian Biomaterial Society as well as the Canadian and Lebanese Societies of Plastic Surgeons, to name a few. He is an international speaker with more than 125 publications, conference proceedings, text-books and patents and is an editorial board member of several national and international scientific journals and periodicals. We appreciate Dr. Maher A. Sughayer for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Nouf N. Mahmoud from Al-Zaytoonah University of Jordan, Amman, Jordan, to join the Editorial Board of Recent Progress in Tumor. Nouf Mahmoud obtained her Ph.D. degree in Pharmaceutical Technology in 2016 from the University of Jordan, and she is an Associate Professor of Pharmaceutics and Nanoscience at Al-Zaytoonah University of Jordan. Nouf’s research focuses on designing functional nanomaterials and nanofibers for several biomedical applications such as wound healing, drug delivery for cancers, and targeting resistant bacterial infections. Furthermore, she is interested in studying nanomaterials’ toxicity, and in Synchrotron-based such as X-ray, FTIR, and 3-D Nano-Tomography for studying nano-bio interface. In her free time, she enjoys cooking and traveling. We appreciate Prof. Dr. Nouf N. Mahmoud for her participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Dr. Avisek Majumder from UCSF School of Medicine, San Francisco, United States, to join the Editorial Board of Recent Progress in Tumor. His main research focus is to understand how HER3 (a member of the EGRF/HER family of receptor tyrosine kinases) functions in physiologic signaling and how this function is perturbed in cancer cells. In one project, He is doing structure-function studies of HER2 and HER3 in HER2-positive breast cancer to identify new structural features that are critical for signaling so that he can develop a new generation of drugs that are both highly effective and have fewer side effects than the current treatment regimen for these patients. In another project, he is working on the development of novel SynNotch CART cell therapy to target HER2-positive breast tumors. Apart from these, he is also involved with several other projects that are currently going on in his lab. We appreciate Dr. Avisek Majumder for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Dr. Pinar Uysal-Onganer from University of Westminster, London, United Kingdom, to join the Editorial Board of Recent Progress in Tumor. Her research experience involves a range of cell signalling mechanisms such as Wnt signalling, the functional and molecular aspects of cancer. She has worked at Imperial College London for 9 years as a Postdoctoral Research Fellow. She has studied on voltage-gated sodium channel (VGSC) expression in metastatic disease at Prof Djamgoz’s laboratory and was first to demonstrate functional upregulation of VGSCs in human small-cell lung cancer, in vitro and in vivo. Then she started collaboration with Baroness Greenfield and demonstrated that an acetylcholinesterase-derived peptide has significant effects on metastatic behaviour of human breast cancer cell lines. Then, she has joined Dr Kypta's lab Prostate Cancer Group at Oncology Dept, Imperial College London and since then have been working on Wnt signalling and microRNAs in cancer. She became a Senior Fellow of HEA at 2018 and a Reader in Molecular Biology in 2022. She has been actively involved in fund-raising activities with charities such as the Cancer Research UK, Pancreatic Cancer UK and the Prostate Cancer Charity (PCC). She is an Athena Swan Coordinator and Cancer Research Group Lead at University of Westminster and run STEMM activities for local schools. We appreciate Dr. Pinar Uysal-Onganer for her participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Gitana Maria Aceto from University of G. d'Annunzio Chieti and Pescara, Chieti, Italy, to join the Editorial Board of Recent Progress in Tumor. She is currently engaged in the study of novel bio-molecular markers of tumour aggressiveness and progression linked to environmental, infectious and pollutant cofactors. In particular, research focuses on the effects of oxidative stress on DNA damage repair molecular pathways, BER and Wnt/β-catenin signalling. We appreciate Prof. Dr. Gitana Maria Aceto for her participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Dr. Annat Raiter from The Felsenstein Medical Research Center, Tel Aviv University Faculty of medicine, Rabin Medical Center, Petach Tikva, Israel, to join the Editorial Board of Recent Progress in Tumor. Dr. Annat Raiter is an outstanding scholar who experts mainly in Breast Cancer, Immunotherapy, Cancer Biology and Cell Signaling. Dr. Annat Raiter has published 40 publications that have been cited over 1000 times with an H-index of 20. We appreciate Dr. Annat Raiter for her participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Sergey К. Efetov from Sechenov First Moscow State Medical University, Moscow, Russian Federation, to join the Editorial Board of Recent Progress in Tumor. Prof. Dr. Sergey К. Efetov is an outstanding scholar who experts mainly in Colon Cancer and Rectal Cancer. He is the Chief of Colorectal surgery department. He has published 62 publications that have been cited over 611 times with an H-index of 14. We appreciate Prof. Dr. Sergey К. Efetov for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Dr. Maher A. Sughayer from Pathology and Laboratory Medicine, King Hussein Cancer Center, Jordan, to join the Editorial Board of Recent Progress in Tumor. Dr. Maher A. Sughayer is an outstanding scholar who experts mainly in Pathology, Cytology, Laboratoey Medicine and Cancer. He is the Chairman of Pathology and Laboratory Medicine, King Hussein Cancer Center. He has published 91 publications that have been cited over 1736 times with an H-index of 22. We appreciate Dr. Maher A. Sughayer for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member
Recent Progress in Tumor Welcomes New Editorial Board Member
We sincerely welcome Prof. Dr. Moshi Geso from RMIT University, Melbourne, Australia, to join the Editorial Board of Recent Progress in Tumor. Since 1991 Dr. Moshi Geso changed field to medical physics and started teaching and research at the department of medical radiations RMIT University as lecturer. In 1998 promoted to senior lecture and 2006 to associate professor. Supervised 15 PhD students to completion in the field of Medical Physics radiations. Most of the projects were based on applications of nanoparticles in radiologic imaging and radiotherapy particularly dosimetry. Also moved into radiobiology where lately involved in few projects in this field where nanomaterials are included in the biological studies. And most of his research at this stage is based on the effects of radiations & metallic nanoparticles on cells. We appreciate Prof. Dr. Moshi Geso for his participation and support.
Read more about Recent Progress in Tumor Welcomes New Editorial Board Member